Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk
By Dean Seal
Lexicon Pharmaceuticals has earned a third $10 million milestone payment from Novo Nordisk for hitting a key milestone in the clinical development program for its obesity drug.
The biopharmaceutical company on Monday said that it has achieved a patient dosing milestone in the continuing phase 1 program for LX9851, a treatment being developed for obesity and associated metabolic disorders.
Lexicon and Novo Nordisk signed an exclusive worldwide license agreement for LX9851 last year, under which Novo Nordisk is able to develop, manufacture and commercialize the drug for all indications.
So far, Lexicon has earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its Novo Nordisk collaboration. Lexicon is also entitled to receive tiered royalties on future LX9851 sales.
The development program for LX9851 was kicked off by Novo Nordisk in March to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of different LX9851 doses compared with a placebo in adult subjects who are overweight or obese.
Phase 1 of the program is expected to be completed in the first quarter of 2027.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 24, 2026 09:27 ET (13:27 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
2 Undervalued Stocks to Buy Before They Rebound
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
United States